作者
Diego Munoz, Aimee M Near, Nicolien T Van Ravesteyn, Sandra J Lee, Clyde B Schechter, Oguzhan Alagoz, Donald A Berry, Elizabeth S Burnside, Yaojen Chang, Gary Chisholm, Harry J De Koning, Mehmet Ali Ergun, Eveline AM Heijnsdijk, Hui Huang, Natasha K Stout, Brian L Sprague, Amy Trentham-Dietz, Jeanne S Mandelblatt, Sylvia K Plevritis
发表日期
2014/11/1
期刊
Journal of the National Cancer Institute
卷号
106
期号
11
页码范围
dju289
出版商
Oxford University Press
简介
Background
Molecular characterization of breast cancer allows subtype-directed interventions. Estrogen receptor (ER) is the longest-established molecular marker.
Methods
We used six established population models with ER-specific input parameters on age-specific incidence, disease natural history, mammography characteristics, and treatment effects to quantify the impact of screening and adjuvant therapy on age-adjusted US breast cancer mortality by ER status from 1975 to 2000. Outcomes included stage-shifts and absolute and relative reductions in mortality; sensitivity analyses evaluated the impact of varying screening frequency or accuracy.
Results
In the year 2000, actual screening and adjuvant treatment reduced breast cancer mortality by a median of 17 per 100000 women (model range = 13–21) and 5 per 100000 women (model range = 3–6 …
学术搜索中的文章
D Munoz, AM Near, NT Van Ravesteyn, SJ Lee… - Journal of the National Cancer Institute, 2014